Craig H. Moskowitz - Concepedia

Author

Craig H. Moskowitz

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

C H Moskowitz, C Moskowitz, C. H Moskowitz, C. H. Moskowitz, C. Moskowitz, C.H. Moskowitz, Craig H Moskowitz, Craig H. Moskowitz, Craig Moskowitz, J. Mehta

534

Publications

22.7K

Citations

H-Index

103

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Dana-Farber Cancer Institute Sylvester Comprehensive Cancer Center City Of Hope National Medical Center

About

Craig H. Moskowitz is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	68	5.8K
2	Health Sciences	19	30	1.7K
3	Nursing	2	2	181
4	Education	1	1	144
5	Social Sciences	1	1	87

Craig H. Moskowitz

196

Publications

21.4K

Citations

H-Index

Page 1

	Year	Citations
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era Christian Gisselbrecht, Nicolas Mounier, Devinder Gill, Journal of Clinical Oncology	2010	1.6K
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma Anas Younes, Ajay K. Gopal, Scott E. Smith, Journal of Clinical Oncology	2012	1.5K
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Journal of Clinical Oncology Surgical OncologyImmunologyPathologyPhase Ii StudyPembrolizumab 200	2017	967
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, The Lancet Lymphoid NeoplasiaCell TherapyTransplantationMarrow TransplantationOncology	2015	726
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure Philippe Armand, Margaret A. Shipp, Vincent Ribrag, Journal of Clinical Oncology	2016	667
Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy, Journal of Clinical Oncology	2004	579
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz, Blood	2001	423
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer, Blood	2004	403
Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, Journal of Clinical Oncology	2005	402
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma Christian Grommes, Alessandro Pastore, Nicolaos Palaskas, Cancer Discovery	2017	390

Page 1